REICH, Kristian et al. Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial. Dermatology Practical & Conceptual, [S. l.], v. 12, n. 2, p. e2022104, 2022. DOI: 10.5826/dpc.1202a104. Disponível em: https://www.dpcj.org/index.php/dpc/article/view/1936.. Acesso em: 15 may. 2026.